BCAR-T:

Caterina Alati1,2, Martina Pitea1,2, Matteo Molica3

  • 1Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", 89133 Reggio Calabria, Italy.

Cancers
|September 27, 2025
PubMed
概括

化学抗原受体T细胞 (CAR-T) 治疗对B细胞急性淋巴细胞白血病 (B-ALL) 是有前途的,但复发仍然是一个挑战. 未来的研究重点是多抗原向和优化CAR-T细胞生产,以获得更好的患者结果.